Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda

Engels, Eric A.; Mbulaiteye, Sam M.; Othieno, Emmanuel; Gomez, Mario; Mathew, Susan; Cesarman, Ethel; Knowles, Daniel M.; Chadburn, Amy

doi:10.1016/j.humpath.2006.08.009

Cited by 14 publications

(10 citation statements)

References 24 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of the tumors tested had HHV8. This is not surprising since an earlier study by Engels and colleges showed only one case of HHV8 positive lymphoma in Ugandan[39]. …”

Section: Discussionmentioning

confidence: 83%

EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda

Tumwine

Orem

Kerchan

et al. 2010

Infect Agents Cancer

View full text Add to dashboard Cite

BackgroundB cell non Hodgkin lymphomas account for the majority of lymphomas in Uganda. The commonest is endemic Burkitt lymphoma, followed by diffuse large-B-cell lymphoma (DLBCL). There has been an increase in incidence of malignant lymphoma since the onset of the HIV/AIDS pandemic. However, the possible linkages of HHV8 and EBV to the condition of impaired immunity present in AIDS are still not yet very clearly understood.Objectives1. To describe the prevalence of Epstein-Barr virus, Human Herpes virus 8 and Human Immunodeficiency Virus-1 in B cell non Hodgkin lymphoma biopsy specimens in Kampala, Uganda.2. To describe the histopathology of non Hodgkin lymphoma by HIV serology test result in Kampala, UgandaMethodTumour biopsies specimens from 119 patients with B cell non Hodgkin lymphoma were classified according to the WHO classification. Immunohistochemistry was used for detection of HHV8 and in situ hybridization with Epstein Barr virus encoded RNA (EBER) for EBV. Real time and nested PCR were used for the detection of HIV.The patients from whom the 1991-2000 NHL biopsies had been taken did not have HIV serology results therefore 145 patients biopsies where serology results were available were used to describe the association of HIV with non Hodgkin lymphoma type during 2008-2009.ResultsIn this study, the majority (92%) of the Burkitt lymphomas and only 34.8% of the diffuse large B cell lymphomas were EBV positive. None of the precursor B lymphoblastic lymphomas or the mantle cell lymphomas showed EBV integration in the lymphoma cells.None of the Burkitt lymphoma biopsies had HIV by PCR. Of the 121 non Hodgkin B cell lymphoma patients with HIV test results, 19% had HIV. However, only 1(0.04%) case of Burkitt lymphoma had HIV. All the tumours were HHV8 negative.ConclusionsThe majority of the Burkitt lymphomas and two fifths of the diffuse large B cell lymphomas had EBV. All the tumours were HHV8 negative. Generally, the relationship of NHL and HIV was weaker than what has been reported from the developed countries. We discuss the role of these viruses in lymphomagenesis in light of current knowledge.

show abstract

“…None of the tumors tested had HHV8. This is not surprising since an earlier study by Engels and colleges showed only one case of HHV8 positive lymphoma in Ugandan[39]. …”

Section: Discussionmentioning

confidence: 83%

EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda

Tumwine

Orem

Kerchan

et al. 2010

Infect Agents Cancer

View full text Add to dashboard Cite

show abstract

“…In this sense, some authors have also agreed that HHV-8 DNA detection in the lymph node would be considered not only as opportunistic infection but also as an agent involved in malignant lymphoproliferation [25]. Furthermore, rare HHV-8 positive solid lymphomas have been described as extra-cavitary PELs forms [26] and Engels and colleagues have previously reported a similar case of NHL from Ugandan pediatric patient [27]. On the other hand, it is possible that HHV-8 may be shed in saliva from HIV infected patient diagnosed with Hodgkin lymphoma, its role in this malignancy has not been established before.…”

Section: Discussionmentioning

confidence: 99%

The Role of Human Herpesvirus 8 Molecular Characterization in the Management of HIV Infected Patients Diagnosed with Malignancies Associated with Its Infection

Ariel¹,

Kourí²,

Blanco³

et al. 2013

WJA

View full text Add to dashboard Cite

Despite the progress has been reached with Human herpesvirus 8 (HHV-8) research, there are gaps in the knowledge of viral induced oncogenesis. The aim of the present study was to identify possible associations between HHV-8 subtypes, HHV-8 loads and clinical manifestations of HIV infected patients diagnosed with different malignancies associated with HHV-8 infection. Forty six HIV-1 infected individuals diagnosed with different HHV-8 associated diseases were studied [37 epidemic Kaposi’s sarcoma (KS), 3 pleural effusion lymphoma (PEL); 5 peripheral lymphadenopathies (PL); 1 Hodgkin’s lymphoma (HL); 1 non Hodgkin’s lymphoma (NHL)]. HHV-8 loads were determined by quantitative real time PCR (qRT-PCR) whilst HHV-8 subtypes were determined by open-reading frame (ORF)-K1 gen genotyping. HHV-8 subtypes B, A, C, A5 and E were exhibited by 31.8%, 23.4%, 19.1%, 17% and 8.5% of the studied patients, respectively. The median HHV-8 viral load did not differ between subtypes (p > 0.05) but HHV-8 viral loads were significantly higher in PEL than in epidemic KS lesion or lymph nodes (p = 0.04). Subtype B was detected in 60% of patients with B cell lymphoma (NHL, PEL and HL) whereas subtype E was only detected in patients with epidemic KS diagnosis. Our data suggest that HHV-8 DNA quantification instead of subtype identification could be used as a surrogate marker for monitoring its infection, not only in epidemic KS patients but also in HIV infected individuals with lymphoproliferative disorders.

show abstract

“…10 Similarly, among 144 cases of NHL and reactive lymphadenopathy in Uganda assessed for KSHV, only 3 (1 NHL, 2 multicentric Castleman disease) were positive. 57 …”

Section: Kshvmentioning

confidence: 99%

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Gopal

Wood

Lee

et al. 2012

Blood

View full text Add to dashboard Cite

Cancer is a leading cause of death and disability in sub-Saharan Africa and will eclipse infectious diseases within the next several decades if current trends continue. Hematologic malignancies, including non-Hodgkin lymphoma, leukemia, Hodgkin lymphoma, and multiple myeloma, account for nearly 10% of the overall cancer burden in the region, and the incidence of non-Hodgkin lymphoma and Hodgkin lymphoma is rapidly increasing as a result of HIV. Despite an increasing burden, mechanisms for diagnosing, treating, and palliating malignant hematologic disorders are inadequate. In this review, we describe the scope of the problem, including the impact of endemic infections, such as HIV, Epstein-Barr virus, malaria, and Kaposi sarcoma–associated herpesvirus. We additionally describe current limitations in hematopathology, chemotherapy, radiotherapy, hematopoietic stem cell transplantation, and supportive care and palliation. We review contemporary treatment and outcomes of hematologic malignancies in the region and outline a clinical service and research agenda, which builds on recent global health successes combating HIV and other infectious diseases. Achieving similar progress against hematologic cancers in sub-Saharan Africa will require the sustained collaboration and advocacy of the entire global cancer community.

show abstract

Kaposi sarcoma-associated herpesvirus in non-Hodgkin lymphoma and reactive lymphadenopathy in Uganda

Cited by 14 publications

References 24 publications

EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda

EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda

The Role of Human Herpesvirus 8 Molecular Characterization in the Management of HIV Infected Patients Diagnosed with Malignancies Associated with Its Infection

Meeting the challenge of hematologic malignancies in sub-Saharan Africa

Contact Info

Product

Resources

About